European journal of preventive cardiology最新文献

筛选
英文 中文
Prognostic impact of high-intensity lipid-lowering therapy under-prescription after acute myocardial infarction in women. 女性急性心肌梗死后高强度降脂治疗处方不足的预后影响。
IF 8.4 2区 医学
European journal of preventive cardiology Pub Date : 2024-11-11 DOI: 10.1093/eurjpc/zwae255
Orianne Weizman, Marie Hauguel-Moreau, Victoria Tea, Franck Albert, Paul Barragan, Jean-Louis Georges, Nicolas Delarche, Mathieu Kerneis, Vincent Bataille, Elodie Drouet, Etienne Puymirat, Jean Ferrières, François Schiele, Tabassome Simon, Nicolas Danchin
{"title":"Prognostic impact of high-intensity lipid-lowering therapy under-prescription after acute myocardial infarction in women.","authors":"Orianne Weizman, Marie Hauguel-Moreau, Victoria Tea, Franck Albert, Paul Barragan, Jean-Louis Georges, Nicolas Delarche, Mathieu Kerneis, Vincent Bataille, Elodie Drouet, Etienne Puymirat, Jean Ferrières, François Schiele, Tabassome Simon, Nicolas Danchin","doi":"10.1093/eurjpc/zwae255","DOIUrl":"10.1093/eurjpc/zwae255","url":null,"abstract":"<p><strong>Aims: </strong>Women are less likely to receive lipid-lowering therapy (LLT) after acute myocardial infarction (AMI). We analysed whether this under-prescription currently persists and has an impact on long-term outcomes.</p><p><strong>Methods and results: </strong>The FAST-MI programme consists of nationwide registries including all patients admitted for AMI ≤ 48 h from onset over a 1 month period in 2005, 2010, and 2015, with long-term follow-up. This analysis focused on high-intensity LLT (atorvastatin ≥ 40 mg or equivalent, or any combination of statin and ezetimibe) in women and men. Women accounted for 28% (N = 3547) of the 12 659 patients. At discharge, high-intensity LLT was significantly less prescribed in women [54 vs. 68% in men, P < 0.001, adjusted odds ratio (OR) 0.78(95% confidence interval (CI) 0.71-0.87)], a trend that did not improve over time: 2005, 25 vs. 35% (P = 0.14); 2010, 66 vs. 79% (P < 0.001); 2015, 67 vs. 79.5% (P = 0.001). In contrast, female sex was not associated with a lack of other recommended treatments at discharge: beta-blockers [adjusted OR 0.98(95% CI 0.88-1.10), P = 0.78], or renin-angiotensin blockers [adjusted OR 0.94(95% CI 0.85-1.03), P = 0.18]. High-intensity LLT at discharge was significantly associated with improved 5 year survival and infarct- and stroke-free survival in women [adjusted hazard ratios (HR) 0.74(95% CI 0.64-0.86), P < 0.001 and adjusted HR: 0.81(95% CI: 0.74-0.89); P < 0.001, respectively]. Similar results were found using a propensity score-matched analysis [HR for 5 year survival in women with high-intensity LLT: 0.82(95% CI 0.70-0.98), P = 0.03].</p><p><strong>Conclusion: </strong>Women suffer from a bias regarding the prescription of high-intensity LLT after AMI, which did not attenuate between 2005 and 2015, with potential consequences on both survival and risk of cardiovascular events.</p>","PeriodicalId":12051,"journal":{"name":"European journal of preventive cardiology","volume":null,"pages":null},"PeriodicalIF":8.4,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142079814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
REDUCE-IT, biomarkers, and confirmation bias: are we missing the forest for the trees? REDUCE-IT、生物标志物和确认偏差:我们是否只见树木不见森林?
IF 8.4 2区 医学
European journal of preventive cardiology Pub Date : 2024-11-11 DOI: 10.1093/eurjpc/zwad169
Samuel C R Sherratt
{"title":"REDUCE-IT, biomarkers, and confirmation bias: are we missing the forest for the trees?","authors":"Samuel C R Sherratt","doi":"10.1093/eurjpc/zwad169","DOIUrl":"10.1093/eurjpc/zwad169","url":null,"abstract":"","PeriodicalId":12051,"journal":{"name":"European journal of preventive cardiology","volume":null,"pages":null},"PeriodicalIF":8.4,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9476980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Use of combination therapy is associated with improved LDL cholesterol management: 1-year follow-up results from the European observational SANTORINI study. 使用联合疗法与改善低密度脂蛋白胆固醇管理有关:欧洲观察性 SANTORINI 研究的 1 年随访结果。
IF 8.4 2区 医学
European journal of preventive cardiology Pub Date : 2024-11-11 DOI: 10.1093/eurjpc/zwae199
Kausik K Ray, Carlos Aguiar, Marcello Arca, Derek L Connolly, Mats Eriksson, Jean Ferrières, Ulrich Laufs, Jose M Mostaza, David Nanchen, Aurélie Bardet, Mathias Lamparter, Richa Chhabra, Jarkko Soronen, Ernst Rietzschel, Timo Strandberg, Hermann Toplak, Frank L J Visseren, Alberico L Catapano
{"title":"Use of combination therapy is associated with improved LDL cholesterol management: 1-year follow-up results from the European observational SANTORINI study.","authors":"Kausik K Ray, Carlos Aguiar, Marcello Arca, Derek L Connolly, Mats Eriksson, Jean Ferrières, Ulrich Laufs, Jose M Mostaza, David Nanchen, Aurélie Bardet, Mathias Lamparter, Richa Chhabra, Jarkko Soronen, Ernst Rietzschel, Timo Strandberg, Hermann Toplak, Frank L J Visseren, Alberico L Catapano","doi":"10.1093/eurjpc/zwae199","DOIUrl":"10.1093/eurjpc/zwae199","url":null,"abstract":"<p><strong>Aims: </strong>To assess whether implementation of the 2019 European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) dyslipidaemia guidelines observed between 2020 and 2021 improved between 2021 and 2022 in the SANTORINI study.</p><p><strong>Methods and results: </strong>Patients with high or very high cardiovascular (CV) risk were recruited across 14 European countries from March 2020 to February 2021, with 1-year prospective follow-up until May 2022. Lipid-lowering therapy (LLT) and 2019 ESC/EAS risk-based low-density lipoprotein (LDL) cholesterol (LDL-C) goal attainment (defined as <1.4 mmol/L for patients at very high CV risk and <1.8 mmol/L for patients at high CV risk) at 1-year follow-up were compared with baseline. Of 9559 patients enrolled, 9136 (2626 high risk and 6504 very high risk) had any available follow-up data, and 7210 (2033 high risk and 5173 very high risk) had baseline and follow-up LDL-C data. Lipid-lowering therapy was escalated in one-third of patients and unchanged in two-thirds. Monotherapy and combination therapy usage rose from 53.6 and 25.6% to 57.1 and 37.9%, respectively. Mean LDL-C levels decreased from 2.4 to 2.0 mmol/L. Goal attainment improved from 21.2 to 30.9%, largely driven by LLT use among those not on LLT at baseline. Goal attainment was greater with combination therapy compared with monotherapy at follow-up (39.4 vs. 25.5%).</p><p><strong>Conclusion: </strong>Lipid-lowering therapy use and achievement of risk-based lipid goals increased over 1-year follow-up particularly when combination LLT was used. Nonetheless, most patients remained above goal; hence, strategies are needed to improve the implementation of combination LLT.</p>","PeriodicalId":12051,"journal":{"name":"European journal of preventive cardiology","volume":null,"pages":null},"PeriodicalIF":8.4,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141305781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In-silico trial emulation to predict the cardiovascular protection of new lipid-lowering drugs: an illustration through the design of the SIRIUS programme. 通过模拟试验来预测新型降脂药物对心血管的保护作用:通过 SIRIUS 计划的设计来说明。
IF 8.4 2区 医学
European journal of preventive cardiology Pub Date : 2024-11-11 DOI: 10.1093/eurjpc/zwae254
Denis Angoulvant, Solène Granjeon-Noriot, Pierre Amarenco, Alexandre Bastien, Emmanuelle Bechet, Franck Boccara, Jean-Pierre Boissel, Bertrand Cariou, Eulalie Courcelles, Alizée Diatchenko, Anne Filipovics, Riad Kahoul, Guillaume Mahé, Emmanuel Peyronnet, Lolita Portal, Solène Porte, Yishu Wang, Philippe Gabriel Steg
{"title":"In-silico trial emulation to predict the cardiovascular protection of new lipid-lowering drugs: an illustration through the design of the SIRIUS programme.","authors":"Denis Angoulvant, Solène Granjeon-Noriot, Pierre Amarenco, Alexandre Bastien, Emmanuelle Bechet, Franck Boccara, Jean-Pierre Boissel, Bertrand Cariou, Eulalie Courcelles, Alizée Diatchenko, Anne Filipovics, Riad Kahoul, Guillaume Mahé, Emmanuel Peyronnet, Lolita Portal, Solène Porte, Yishu Wang, Philippe Gabriel Steg","doi":"10.1093/eurjpc/zwae254","DOIUrl":"10.1093/eurjpc/zwae254","url":null,"abstract":"<p><strong>Introduction: </strong>Inclisiran, an siRNA targeting hepatic PCSK9 mRNA, administered twice-yearly (after initial and 3-month doses), substantially and sustainably reduced LDL-cholesterol (LDL-C) in Phase III trials. Whether lowering LDL-C with inclisiran translates into a reduced risk of major adverse cardiovascular events (MACE) is not yet established. In-silico trials applying a disease computational model to virtual patients receiving new treatments allow to emulate large scale long-term clinical trials. The SIRIUS in-silico trial programme aims to predict the efficacy of inclisiran on CV events in individuals with established atherosclerotic cardiovascular disease (ASCVD).</p><p><strong>Methods and results: </strong>A knowledge-based mechanistic model of ASCVD was built, calibrated, and validated to conduct the SIRIUS programme (NCT05974345) aiming to predict the effect of inclisiran on CV outcomes. The SIRIUS Virtual Population included patients with established ASCVD (previous myocardial infarction (MI), previous ischemic stroke (IS), previous symptomatic lower limb peripheral arterial disease (PAD) defined as either intermittent claudication with ankle-brachial index <0.85, prior peripheral arterial revascularization procedure, or vascular amputation) and fasting LDL-C ≥ 70 mg/dL, despite stable (≥4 weeks) well-tolerated lipid-lowering therapies.SIRIUS is an in-silico multi-arm trial programme. It follows an idealized crossover design where each virtual patient is its own control, comparing inclisiran to (i) placebo as adjunct to high-intensity statin therapy with or without ezetimibe, (ii) ezetimibe as adjunct to high-intensity statin therapy, (iii) evolocumab as adjunct to high-intensity statin therapy and ezetimibe.The co-primary efficacy outcomes are based on the time to the first occurrence of any component of 3P-MACE (composite of CV death, nonfatal MI, or nonfatal IS) and time to occurrence of CV death over 5 years.</p><p><strong>Perspectives/conclusion: </strong>The SIRIUS in-silico trial programme will provide early insights regarding potential effect of inclisiran on MACE in ASCVD patients, several years before the availability of the results from ongoing CV outcomes trials (ORION-4 and VICTORION-2-P).</p><p><strong>Clinical trial registration: </strong>Clinicaltrials.gov identifier: NCT05974345.</p>","PeriodicalId":12051,"journal":{"name":"European journal of preventive cardiology","volume":null,"pages":null},"PeriodicalIF":8.4,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141888833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to: Lipoprotein(a): Don't forget about secondary prevention. 更正为脂蛋白(a):不要忘记二级预防。
IF 8.4 2区 医学
European journal of preventive cardiology Pub Date : 2024-11-11 DOI: 10.1093/eurjpc/zwae311
{"title":"Correction to: Lipoprotein(a): Don't forget about secondary prevention.","authors":"","doi":"10.1093/eurjpc/zwae311","DOIUrl":"10.1093/eurjpc/zwae311","url":null,"abstract":"","PeriodicalId":12051,"journal":{"name":"European journal of preventive cardiology","volume":null,"pages":null},"PeriodicalIF":8.4,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142344259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effects of omega-3 fatty acids on coronary revascularization and cardiovascular events: is there a role for fibrates? A reply. 欧米伽-3 脂肪酸对冠状动脉血运重建和心血管事件的影响:纤维酸盐是否有作用?
IF 8.4 2区 医学
European journal of preventive cardiology Pub Date : 2024-11-11 DOI: 10.1093/eurjpc/zwae234
Giuseppe Ambrosio
{"title":"Effects of omega-3 fatty acids on coronary revascularization and cardiovascular events: is there a role for fibrates? A reply.","authors":"Giuseppe Ambrosio","doi":"10.1093/eurjpc/zwae234","DOIUrl":"10.1093/eurjpc/zwae234","url":null,"abstract":"","PeriodicalId":12051,"journal":{"name":"European journal of preventive cardiology","volume":null,"pages":null},"PeriodicalIF":8.4,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141758011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lipid-lowering therapy after myocardial infarction: strike early, strong, and equally in women and men. 心肌梗死后的降脂治疗:早出击、强出击,男女平等。
IF 8.4 2区 医学
European journal of preventive cardiology Pub Date : 2024-11-11 DOI: 10.1093/eurjpc/zwae319
Gal Tsaban, Barbara Vitola
{"title":"Lipid-lowering therapy after myocardial infarction: strike early, strong, and equally in women and men.","authors":"Gal Tsaban, Barbara Vitola","doi":"10.1093/eurjpc/zwae319","DOIUrl":"10.1093/eurjpc/zwae319","url":null,"abstract":"","PeriodicalId":12051,"journal":{"name":"European journal of preventive cardiology","volume":null,"pages":null},"PeriodicalIF":8.4,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142344264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lipoprotein(a) and long-term in-stent restenosis after percutaneous coronary intervention. 脂蛋白(a)与经皮冠状动脉介入术后支架内长期再狭窄
IF 8.4 2区 医学
European journal of preventive cardiology Pub Date : 2024-11-11 DOI: 10.1093/eurjpc/zwae212
Ahmed K Mahmoud, Juan M Farina, Kamal Awad, Nima Baba Ali, Milagros Pereyra, Isabel G Scalia, Mohammed Tiseer Abbas, Mohamed N Allam, Moaz A Kamel, Anan A Abu Rmilah, Chieh-Ju Chao, Timothy Barry, Said Alsidawi, Steven J Lester, Peter M Pollak, Mohamad A Alkhouli, Kwan S Lee, Eric H Yang, Richard W Lee, John P Sweeney, David F Fortuin, Chadi Ayoub, Reza Arsanjani
{"title":"Lipoprotein(a) and long-term in-stent restenosis after percutaneous coronary intervention.","authors":"Ahmed K Mahmoud, Juan M Farina, Kamal Awad, Nima Baba Ali, Milagros Pereyra, Isabel G Scalia, Mohammed Tiseer Abbas, Mohamed N Allam, Moaz A Kamel, Anan A Abu Rmilah, Chieh-Ju Chao, Timothy Barry, Said Alsidawi, Steven J Lester, Peter M Pollak, Mohamad A Alkhouli, Kwan S Lee, Eric H Yang, Richard W Lee, John P Sweeney, David F Fortuin, Chadi Ayoub, Reza Arsanjani","doi":"10.1093/eurjpc/zwae212","DOIUrl":"10.1093/eurjpc/zwae212","url":null,"abstract":"<p><strong>Aims: </strong>Lipoprotein(a) [Lp(a)] has demonstrated its association with atherosclerosis and myocardial infarction. However, its role in the development of in-stent restenosis (ISR) after percutaneous coronary intervention (PCI) is not clearly established. The aim of this study is to investigate the association between Lp(a) and ISR.</p><p><strong>Methods and results: </strong>A retrospective study of adult patients who underwent successful PCI between January 2006 and December 2017 at the three Mayo Clinic sites and had a preprocedural Lp(a) measurement was conducted. Patients were divided into two groups according to the serum Lp(a) concentration [high Lp(a) ≥ 50 mg/dL and low Lp(a) < 50 mg/dL]. Univariable and multivariable analyses were performed to compare risk of ISR between patients with high Lp(a) vs. those with low Lp(a). A total of 1209 patients were included, with mean age 65.9 ± 11.7 years and 71.8% were male. Median follow-up after baseline PCI was 8.8 [interquartile range (IQR) 7.4] years. Restenosis was observed in 162 (13.4%) patients. Median serum levels of Lp(a) were significantly higher in patients affected by ISR vs. non-affected cases: 27 (IQR 73.8) vs. 20 (IQR 57.5) mg/dL, P = 0.008. The rate of ISR was significantly higher among patients with high Lp(a) vs. patients with low Lp(a) values (17.0% vs. 11.6%, P = 0.010). High Lp(a) values were independently associated with ISR events (hazard ratio 1.67, 95% confidence interval 1.18-2.37, P = 0.004), and this association was more prominent after the first year following the PCI.</p><p><strong>Conclusion: </strong>Lipoprotein(a) is an independent predictor for long-term ISR and should be considered in the evaluation of patients undergoing PCI.</p>","PeriodicalId":12051,"journal":{"name":"European journal of preventive cardiology","volume":null,"pages":null},"PeriodicalIF":8.4,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141445939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effects of omega-3 fatty acids on coronary revascularization and cardiovascular events: is there a role for fibrates? 欧米伽-3 脂肪酸对冠状动脉血运重建和心血管事件的影响:纤维酸盐是否有作用?
IF 8.4 2区 医学
European journal of preventive cardiology Pub Date : 2024-11-11 DOI: 10.1093/eurjpc/zwae247
Francesco Sbrana, Beatrice Dal Pino
{"title":"Effects of omega-3 fatty acids on coronary revascularization and cardiovascular events: is there a role for fibrates?","authors":"Francesco Sbrana, Beatrice Dal Pino","doi":"10.1093/eurjpc/zwae247","DOIUrl":"10.1093/eurjpc/zwae247","url":null,"abstract":"","PeriodicalId":12051,"journal":{"name":"European journal of preventive cardiology","volume":null,"pages":null},"PeriodicalIF":8.4,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141787733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lipoprotein(a): Don't forget about secondary prevention. 脂蛋白(a):不要忘记二级预防。
IF 8.4 2区 医学
European journal of preventive cardiology Pub Date : 2024-11-11 DOI: 10.1093/eurjpc/zwae276
Harpreet S Bhatia, Franck Boccara
{"title":"Lipoprotein(a): Don't forget about secondary prevention.","authors":"Harpreet S Bhatia, Franck Boccara","doi":"10.1093/eurjpc/zwae276","DOIUrl":"10.1093/eurjpc/zwae276","url":null,"abstract":"","PeriodicalId":12051,"journal":{"name":"European journal of preventive cardiology","volume":null,"pages":null},"PeriodicalIF":8.4,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142016807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信